NCT07274735 Combined Effects of INF and OEP in Patients With Diabetic Peripheral Neuropathy
| NCT ID | NCT07274735 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Riphah International University |
| Condition | Diabetic Peripheral Neuropathy |
| Study Type | INTERVENTIONAL |
| Enrollment | 65 participants |
| Start Date | 2024-10-17 |
| Primary Completion | 2026-01-17 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 65 participants in total. It began in 2024-10-17 with a primary completion date of 2026-01-17.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
DPN often leads to balance issues, sensory deficits, and chronic pain, which can severely impact daily functioning and independence. INF therapy aims to improve nerve blood flow and alleviate neuropathic symptoms through manual techniques, while the Otago Exercise Program focuses on enhancing strength and balance to reduce fall risk. By comparing these two interventions, this study seeks to identify effective strategies that can improve balance, reduce pain, and enhance the quality of life for individuals suffering from DPN
Eligibility Criteria
Inclusion Criteria: * Age 50-75years * Both male and female patients will be included in the study * Patient with type 2 diabetes mellitus (diagnosed by the physician) * Patients with a score ≥ 4 on DN4 scale * Patients have a score on the Timed Up-and-Go (TUG) test of less than 15 s * Able to walk at least 10 meters long Exclusion Criteria: * Patient with presence of any other systemic disease rather than diabetes such as end-stage renal failure, uncontrolled hypertension, severe dyslipidemia, chronic liver disease, autoimmune disease, advanced chronic obstructive pulmonary disease etc * Patients with documented active alcohol or drug misuse * Patient with total or partial amputation of lower extremities * Participants will be also excluded if they were morbidly obese or if pregnant (self-reported) * Patient with active inflammations or other inflammatory neuropathies including chronic inflammatory demyelinating polyneuropathy, proximal diabetic neuropathy, chemotherapy-induced peripheral neuropathy, autonomic neuropathies, or other neuropathies not associated with DM such as B12 deficiency
Contact & Investigator
Aruba Saeed, PhD
PRINCIPAL INVESTIGATOR
Riphah International University
Frequently Asked Questions
Who can join the NCT07274735 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 75 Years, studying Diabetic Peripheral Neuropathy. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07274735 currently recruiting?
Yes, NCT07274735 is actively recruiting participants. Contact the research team at imran.amjad@riphah.edu.pk for enrollment information.
Where is the NCT07274735 trial being conducted?
This trial is being conducted at Lahore, Pakistan.
Who is sponsoring the NCT07274735 clinical trial?
NCT07274735 is sponsored by Riphah International University. The principal investigator is Aruba Saeed, PhD at Riphah International University. The trial plans to enroll 65 participants.